Integrating downstream mediators of Omega-3 fatty acids into enteral nutrition for improved patient care: An expert panel consensus.
Level 5 - mechanism / opinion, no new human data
Delphi-based expert panel consensus statement and review without primary clinical trial data
PubMed 41406625 · doi:10.1016/j.clnu.2025.11.014
What was done
A multidisciplinary expert panel conducted a Delphi-based consensus process to evaluate the biological rationale and clinical potential of enriching enteral nutrition with preformed specialized pro-resolving mediators (SPMs, including resolvins, protectins, and maresins) or their stable precursors derived from omega-3 polyunsaturated fatty acids (EPA and DHA).
What was found
The abstract reports no quantitative data or statistical effect estimates. The panel reached consensus supporting the enrichment of enteral nutrition with preformed SPMs or their precursors to bypass impaired endogenous biosynthesis in inflammatory disease states. The panel highlighted preliminary human studies suggesting potential benefits in inflammation reduction and immune function across obesity, atherosclerosis, infections, and chronic pain, but concluded that formal clinical trials are required to determine measurable clinical efficacy and optimal dosing.
Why it matters
This consensus formalizes an expert rationale for moving beyond parent omega-3 fatty acid supplementation to direct downstream mediator delivery in clinical enteral nutrition.
Limits
The abstract provides no primary empirical data, quantitative findings, or panel sample size. The recommendations represent expert opinion based on preliminary mechanistic and clinical signals rather than established clinical trial evidence.
Cited by
- supports Specialized pro-resolving mediators derived from omega-3 fatty acids include resolvins, protectins, and maresins.